Search Results

You are looking at 261 - 270 of 489 items for :

  • "paclitaxel" x
  • Refine by Access: All x
Clear All
Full access

Response to Targeted Therapy in BRAF Mutant Anaplastic Thyroid Cancer

Rishi Agarwal, Jiang Wang, Keith Wilson, William Barrett, and John C. Morris

chemotherapy agents, including bleomycin, carboplatin, cisplatin, docetaxel, doxorubicin, and paclitaxel, used in various combinations, have been reported to have palliative benefit in small nonrandomized trials, but little impact on survival. 1 , 3 , 4 As a

Full access

Breast Cancer, Version 3.2013

Richard L. Theriault, Robert W. Carlson, Craig Allred, Benjamin O. Anderson, Harold J. Burstein, Stephen B. Edge, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Steven J. Isakoff, Britt-Marie E. Ljung, David A. Mankoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth C. Reed, Lee S. Schwartzberg, Mary Lou Smith, Hatem Soliman, George Somlo, John H. Ward, Antonio C. Wolff, Richard Zellars, Dorothy A. Shead, and Rashmi Kumar

together with other active cytotoxics, such as paclitaxel and vinorelbine 14 , 15 ( ClinicalTrials.gov identifier: NCT01276041). Phase III trials of pertuzumab plus chemotherapy without trastuzumab have not been reported. Pertuzumab has antitumor

Full access

Durable Complete Response With Immune Checkpoint Inhibitor in Breast Cancer With High Tumor Mutational Burden and APOBEC Signature

Saranya Chumsri, Ethan S. Sokol, Aixa E. Soyano-Muller, Ricardo D. Parrondo, Gina A. Reynolds, Aziza Nassar, and E. Aubrey Thompson

doxorubicin and cyclophosphamide every 2 weeks for 4 cycles followed by weekly paclitaxel for 12 weeks. Follow-up CT of the chest, abdomen, and pelvis after neoadjuvant chemotherapy showed a partial response with no evidence of distant metastases. The patient

Full access

Bevacizumab for Recurrent Glioblastoma Multiforme: A Meta-Analysis

Eric T. Wong, Shiva Gautam, Christopher Malchow, Melody Lun, Edward Pan, and Steven Brem

significant. 11 In metastatic non–small cell lung cancer, the benefit of bevacizumab at 15 mg/kg every 3 weeks was only slightly higher than at a lower dose of 7.5 mg/kg when both drugs were combined with carboplatin and paclitaxel. 12 The higher bevacizumab

Full access

First-Line Treatment of Widely Metastatic BRAF-Mutated Salivary Duct Carcinoma With Combined BRAF and MEK Inhibition

Victor T.G. Lin, Lisle M. Nabell, Sharon A. Spencer, William R. Carroll, Shuko Harada, and Eddy S. Yang

benefit to treatment with combined carboplatin and paclitaxel. 6 Notably, this cohort of 18 patients was established from a retrospective review of >8 years of clinical records, which exemplifies the difficulty of performing robust prospective clinical

Full access

NCCN Guidelines Updates: Breast Cancer

Melinda L. Telli, William J. Gradishar, and John H. Ward

well. In IMpassion130, patients with triple-negative breast cancer were randomized to receive albumen-bound (nab) paclitaxel alone or with atezolizumab in the first-line setting. Among PD-L1–positive patients, progression-free survival improved from 5

Full access

Thymic Malignancies*

David S. Ettinger, Wallace Akerley, Gerold Bepler, Matthew G. Blum, Andrew Chang, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D'Amico, Todd L. Demmy, Ramaswamy Govindan, Frederic W. Grannis Jr., Thierry Jahan, David H. Johnson, Anne Kessinger, Ritsuko Komaki, Feng-Ming Kong, Mark G. Kris, Lee M. Krug, Quynh-Thu Le, Inga T. Lennes, Renato Martins, Janis O'Malley, Raymond U. Osarogiagbon, Gregory A. Otterson, Jyoti D. Patel, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Eric Rohren, Scott J. Swanson, Douglas E. Wood, and Stephen C. Yang

treatment for advanced invasive thymoma with cisplatin, doxorubicin, and methylprednisolone . J Thorac Oncol 2007 ; 2 : 73 – 78 . 31. Lemma GL Loehrer PJ Sr Lee JW . A phase II study of carboplatin plus paclitaxel in advanced thymoma or thymic

Full access

Sequencing Therapy for Patients With Lung Cancer

Presented by: Gregory J. Riely

<1%), the hazard ratio for OS was 0.59.” Pembrolizumab is not the only immunotherapy drug to demonstrate value when given in combination with chemotherapy. The addition of atezolizumab to carboplatin/paclitaxel/bevacizumab also demonstrated a

Full access

Modern Approaches to Localized Cancer of the Esophagus

Robert E. Glasgow, David H. Ilson, James A. Hayman, Hans Gerdes, Mary F. Mulcahy, and Jaffer A. Ajani

over surgery alone in esophageal and gastroesophageal junction adenocarcinoma and squamous cancer. 45 This trial also used a more contemporary chemotherapy regimen: weekly carboplatin plus paclitaxel. Preoperative therapy conferred a median 2-year

Full access

NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018

A. Dimitrios Colevas, Sue S. Yom, David G. Pfister, Sharon Spencer, David Adelstein, Douglas Adkins, David M. Brizel, Barbara Burtness, Paul M. Busse, Jimmy J. Caudell, Anthony J. Cmelak, David W. Eisele, Moon Fenton, Robert L. Foote, Jill Gilbert, Maura L. Gillison, Robert I. Haddad, Wesley L. Hicks Jr, Ying J. Hitchcock, Antonio Jimeno, Debra Leizman, Ellie Maghami, Loren K. Mell, Bharat B. Mittal, Harlan A. Pinto, John A. Ridge, James Rocco, Cristina P. Rodriguez, Jatin P. Shah, Randal S. Weber, Matthew Witek, Frank Worden, Weining Zhen, Jennifer L. Burns, and Susan D. Darlow

cisplatin/5-FU or cisplatin/paclitaxel. 49 However, results from a recent randomized phase III trial showed that patients with recurrent or metastatic NPC (N=362) who received gemcitabine/cisplatin had a greater median PFS compared with those who received